Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Claudia Nicolay"'
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-11 (2023)
Abstract Background Patients with type 2 diabetes (T2D) treated with glucagon-like peptide-1 receptor agonists may experience reductions in weight and blood pressure. The primary objective of the current study was to determine the weight-dependent an
Externí odkaz:
https://doaj.org/article/906aee6f13da4762a9d6c90e02b90f72
Autor:
Edward Franek, Prem Pais, Jan Basile, Claudia Nicolay, Sohini Raha, Ana Hickey, Nadia N. Ahmad, Manige Konig, Hong Kan, Hertzel C. Gerstein
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background In clinical practice, anthropometric measures other than BMI are rarely assessed yet may be more predictive of cardiovascular (CV) risk. We analyzed the placebo group of the REWIND CV Outcomes Trial to compare several anthropometr
Externí odkaz:
https://doaj.org/article/36ebe7b89edb44f4a7c1ae1311e3da98
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 7, Iss 1 (2020)
**Background/Objectives:** This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (M
Externí odkaz:
https://doaj.org/article/865c720fda474b15a945c23037a50c37
Autor:
Sue D. Pedersen, Francesco Giorgino, Guillermo Umpierrez, Vivian T. Thieu, Angel Rodríguez, Claudia Nicolay, Laura Fernández Landó, Chrisanthi A. Karanikas, Jacek Kiljanski
Publikováno v:
Diabetes, Obesity and Metabolism.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6076ec503b5f7765d1e84ee0030e9bd0
https://doi.org/10.1111/dom.15140
https://doi.org/10.1111/dom.15140
Autor:
Edward Franek, Hertzel C. Gerstein, Matthew C. Riddle, Claudia Nicolay, Ana Hickey, Fady T. Botros, Li Shen Loo
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1753-1761
To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.Intention-to-treat analyses were performed on R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66ecb6b7bd2036b3e9eb88e99d54e59
https://doi.org/10.1111/dom.14760
https://doi.org/10.1111/dom.14760
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1770-1778
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5c7e51669ab3ae46737d8f1ffd0f6b8
https://doi.org/10.1111/dom.14762
https://doi.org/10.1111/dom.14762
Publikováno v:
Diabetes, obesitymetabolism. 24(9)
This post hoc analysis investigated the effect of dulaglutide on cardiovascular disease (CVD) risk factors in subgroups of participants at increased CVD risk in the AWARD-11 study.Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec934ec086f98c0ad859c9fb053b2607
https://pubmed.ncbi.nlm.nih.gov/35546790
https://pubmed.ncbi.nlm.nih.gov/35546790
Publikováno v:
Journal of Health Economics and Outcomes Research
Background/Objectives: This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (MTX),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d628a1fc26553e69bdaafec71cc8cc27
http://europepmc.org/articles/PMC7299462
http://europepmc.org/articles/PMC7299462
Publikováno v:
Pharmacoeconomics
Background/Objective Baricitinib is a selective and reversible Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284b25a8cb00c399cfebabc369dadead
https://doi.org/10.1007/s40273-019-00829-x
https://doi.org/10.1007/s40273-019-00829-x
Autor:
Martijn A. H. Oude Voshaar, Inmaculada de la Torre, Mart A F J van de Laar, Peter M. ten Klooster, Claudia Nicolay, Walid D. Fakhouri
Publikováno v:
Clinical rheumatology, 38(10), 2727-2736. Springer
OBJECTIVE: To retrospectively compare the long-term clinical, functional, and cost outcomes for early RA patients (symptoms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea5dde4a28a0f4a4f28eda4654730a0b
https://doi.org/10.1007/s10067-019-04600-7
https://doi.org/10.1007/s10067-019-04600-7